|Back to Main Print This Page Email to a Friend|
Hemolytic disease of the newborn (HDN) is a blood disorder in a fetus or newborn infant. In some infants, it can be life-threatening.
This article provides a general overview. For more detailed information, see the specific disorder:
HDN; Erythroblastosis fetalis
HDN may develop when a mother and her unborn baby have different blood types (called "incompatibility"). The mother produces substances called antibodies that attack the developing baby's red blood cells.
The most common form of HDN is ABO incompatibility, which is usually not very severe. Other, less common types may cause more severe problems.
The least common form is Rh incompatibility, which can almost always be prevented. When this form does occur, it can cause very severe anemia in the baby.
HDN can destroy the newborn baby's blood cells very quickly, which can cause symptoms such as:
Signs of HDN include:
Which tests are done depends on the type of blood group incompatibility and the severity of symptoms, but may include:
After birth, a transfusion may need to be performed.
Infants with mild HDN may be treated with:
The severity of this condition can vary. Some babies have no symptoms. In other cases, problems such as hydrops can cause the baby to die before, or shortly after birth. Severe HDN may be treated before birth by intrauterine blood transfusion.
The most severe form of this disease, which is caused by Rh incompatibility, can be prevented if the mother is given a shot of a medicine called RhoGAM at certain times during and after her pregnancy. If you have had a baby with this disease, talk with your doctor if you plan to have another baby.
Gruslin AM, Moore TR. Erythroblastosis fetalis. In: Martin R, Fanaroff A, Walsh M, eds. Neonatal-Perinatal Medicine. 9th ed. Philadelphia, Pa: Mosby Elsevier; 2011.
Cohen DW. Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues. UpToDate [online]. Waltham, Ma: Nov 2009.